Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TGA Sciences (TGA) has entered into a co-marketing agreement with Sanguine BioSciences as per which Sanguine will market TGA's Bioassay Development services in conjunction with its product offering, including PBMC and biospecimen from healthy and patient donors.
Subscribe to our email newsletter
As Sanguine increases its presence on the biomarker development front, the company’s clients will demand bioassay development services, and TGA is now well positioned to receive a larger volume of requests for biomarker development services, the company claimed.
Sanguine Biospecimen Marketing Vice President David Winternheimer said the deal with TGA would help them provide additional services from a CRO with experience in cell-based bioassays.
"We are excited to enter into this co-marketing agreement with Sanguine, and are hopeful it will help us expand our client base in Europe as well as help us increase the scope of our bioassay services," Winternheimer added.